Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for hard-to-treat head and neck cancer?

NCT ID NCT07136545

Recruiting now Disease control Sponsor: Taipei Veterans General Hospital, Taiwan Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 31 times

Summary

This study tests a new drug (HCB101) combined with an existing immunotherapy (pembrolizumab) for people with advanced head and neck cancer that no longer responds to platinum chemotherapy. About 50 adults will receive the combination to see if it is safe and can shrink tumors or slow the disease. The goal is to better control the cancer, not to cure it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HNSCC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Chang-Gung Memorial Hospital(Lin-Kou)

    RECRUITING

    Taoyuan, Guishan District, 333, Taiwan

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • National Taiwan University Hospital

    RECRUITING

    Taipei, Taipei city, 100, Taiwan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Taipei Veterans General Hospital

    RECRUITING

    Taipei, taipei city, 112, Taiwan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.

HNSCC